Simponi vs Stelara for Ulcerative Colitis: How They Compare

Simponi and Stelara are two subcutaneous biologics for moderate-to-severe ulcerative colitis that work through fundamentally different mechanisms. Simponi (golimumab) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the simponi vs stelara ulcerative colitis decision.

Anti-TNF vs IL-12/23 Mechanism

Simponi binds TNF-alpha and reduces inflammation throughout the body and in the colon. Stelara binds the p40 subunit shared by IL-12 and IL-23, blocking both cytokines. IL-23 is a central driver of Th17-mediated inflammation in UC, while IL-12 contributes to Th1 inflammation. The golimumab vs ustekinumab UC distinction shapes both speed of onset and the long-term safety profile. Simponi's broader TNF blockade produces faster systemic anti-inflammatory effects. Stelara's IL-12/23 inhibition produces strong efficacy with a cleaner infection profile.

UC Efficacy Data

Simponi's UC efficacy rests on PURSUIT-SC (induction) and PURSUIT-M (maintenance), which established golimumab as an effective SC anti-TNF for UC. Stelara's UC efficacy rests on UNIFI, which showed clinical remission rates at week 8 significantly better than placebo, with sustained remission through week 44. No head-to-head trial has directly compared Simponi with Stelara in UC. Indirect comparisons suggest Stelara produces comparable or somewhat stronger clinical remission rates, with particular advantage in biologic-experienced patients.

Onset of Action

Simponi produces meaningful UC response by week 6 based on PURSUIT-SC. Stelara's UC onset produces meaningful response by week 8 based on UNIFI. For UC patients with active symptoms, the two drugs have comparable onset timelines, and individual response variability often matters more than these small differences in trial endpoints.

Safety Profiles

Simponi carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Stelara's long-term safety data from more than a decade of post-marketing experience in psoriasis, Crohn's, and UC shows low rates of serious infection. For simponi vs stelara side effects, Stelara's IL-12/23 mechanism is often associated with fewer systemic infections than anti-TNFs. Both drugs require TB and hepatitis B screening before starting.

IL-12/23 vs Anti-TNF UC

For patients who have failed or lost response to an anti-TNF like Simponi, a mechanism switch to Stelara's IL-12/23 pathway is supported by UNIFI data. Cycling within the anti-TNF class (for example, to Humira from Simponi) typically delivers lower response rates than changing mechanism classes. For first-line UC patients weighing these two options, both are reasonable starting points, with Simponi favored for patients who want fully SC therapy throughout and Stelara favored for those prioritizing long-term safety.

Administration and Dosing

Simponi for UC uses 200 mg SC at week 0, 100 mg at week 2, and then 100 mg every 4 weeks for maintenance, per Janssen's prescribing information. Simponi is all-SC throughout. Stelara starts with weight-based IV induction at week 0 (dose 260-520 mg based on weight), followed by subcutaneous maintenance of 90 mg every 8 weeks, per Janssen's Stelara prescribing information. For UC patients comparing administration, Simponi is fully SC, while Stelara requires one IV infusion before transitioning to SC maintenance. Stelara's every-8-week maintenance cadence is less frequent than Simponi's every-4-week schedule.

Extraintestinal Manifestations

Both Simponi and Stelara treat UC-associated extraintestinal manifestations, though through different pathways. Simponi, as an anti-TNF, has broad coverage of peripheral arthritis, ankylosing spondylitis, and certain skin conditions. Stelara has strong data in psoriatic arthritis and psoriasis through its IL-12/23 mechanism. For UC patients with specific extraintestinal conditions, the choice can depend on which mechanism better covers their comorbid disease.

Biosimilar Availability

Stelara's patent expired in 2023, and ustekinumab biosimilars launched in the US market beginning in 2025, which may lower acquisition costs for Stelara going forward. Simponi's SC formulation currently lacks widely available biosimilars in the US market. For UC patients where insurance favors a lower-cost ustekinumab biosimilar, Stelara (or its biosimilar) may be the most accessible option.

Choosing With Your GI

For a UC patient deciding between Simponi and Stelara, Simponi tends to win on fully SC administration throughout and broad extraintestinal manifestation coverage. Stelara tends to win on long-term safety, less frequent SC maintenance (every 8 weeks vs every 4 weeks), performance in anti-TNF experienced patients, and biosimilar cost savings. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles each option. A log of stool frequency, urgency, blood, and any new extraintestinal symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.